FREDERICK, MD., (April 29, 2025) —RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S. – Age-Reversed Stem Cell Technology Now Available to the Public –
Palo Alto, CA – I Peace, Inc., a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalized iPS cell production and longevity-focused rejuvenation therapies in the United States.
I Peace CEO Koji Tanabe spoke at the “Unlimited Health Conference,” a part of the Vitalist Bay, the biggest longevity event in the world, which is held in Berkeley, California. The event was held on April 5. [Read more…]
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies
Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next
-
Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
-
Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
-
Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.
Cellino and Matricelf Collaborate to Scale iPSC-Derived Treatments for Spinal Cord Injury (SCI)
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.
Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.
CAMBRIDGE, Mass. – Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 144
- Next Page »